-
Sector Analysis
NewBronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Bronchiectasis Market Report Overview The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis. Bronchiectasis Market...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ivarmacitinib Sulfate in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivarmacitinib Sulfate in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivarmacitinib Sulfate in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ivarmacitinib Sulfate in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivarmacitinib Sulfate in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivarmacitinib Sulfate in Alopecia Areata Drug Details: SHR-0302 (ARQ-250) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Grapiprant in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Grapiprant in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Grapiprant in Colorectal Cancer Drug Details: Grapiprant (RQ-0000007, RQ-7, MR10A7) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Acalabrutinib Maleate in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acalabrutinib Maleate in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acalabrutinib Maleate in Follicular Lymphoma Drug Details: Acalabrutinib maleate (Calquence) is...
-
Product Insights
Bronchiectasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchiectasis - Drugs In Development, 2023’, provides an overview of the Bronchiectasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Alopecia Areata – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia Areata - Drugs In Development, 2023’, provides an overview of the Alopecia Areata pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia Areata, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RS-2102 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RS-2102 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RS-2102 in Atopic Dermatitis (Atopic Eczema) Drug Details: RS-2102 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RS-1805 in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RS-1805 in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RS-1805 in Crohn's Disease (Regional Enteritis) Drug Details:RS-1805 is under development...